AID Group, together with its Thai and Hong Kong partners, established Thai Omics as Thailand's exclusive genome sequencing centre for Genomics Thailand — the national initiative to sequence 80,000 whole genomes across rare disease, cancer, pharmacogenomics, and population genetics cohorts. The joint venture brings together Thai institutional partners with regulatory and clinical reach inside the country, Hong Kong co-investors with deep precision-medicine experience, and AID Group as the operating shareholder. The facility is located in Thailand's Eastern Economic Corridor at Burapha University in Chonburi, with Thai Board of Investment (BOI) support.
Thai Omics complements AID Genomics in Israel and gives AID Group meaningful exposure to the genomic data layer across two rapidly developing precision-medicine markets. The Thai facility specialises in whole-genome sequencing on Illumina NovaSeq platforms; the Israeli facilities specialise in molecular diagnostics, oncology, and hereditary disease.
The investment is a long-hold thesis. "Sovereign-scale genomic infrastructure is built once," Snir Zano observed in 2023. "We want to be the operator countries call when they decide to build it — and we are best positioned to be that operator when we partner with the institutions on the ground."
AI.D Group · Chonburi, Thailand